Studio City International Holdings Limited reported a drop in total operating revenues to $163.3 million in Q3 2026 from $182.5 million a year earlier, mainly due to weaker mass market gaming and lower non-gaming revenues. The casino's gross gaming revenue fell to $320.9 million from $344.4 million, while operating income declined to $14.7 million from $23.9 million. Despite a net loss of $13.1 million, the loss narrowed compared to $18.6 million in Q3 2025. The company also renewed its land concession for ten years, ensuring operational continuity. Investors should watch for how Studio City manages its debt and revenue challenges going forward.
Studio City International Holdings Limited's Q3 2026 earnings provide context for readers following consumer cyclical stocks. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: Out of 134 priced US stocks, 113 rose and 16 fell today. Among notable movers, Lennar Corporation (LEN) rose 4.02% to USD 89.55 with a typical hold time of 69 days and 100% buy order activity, D R Horton Inc (DHI) increased 3.99% to USD 151.02 with a typical hold time of 47 days, and MGM Resorts International (MGM) gained 3.77% to USD 32.19 with a typical hold time of 93 days and 100% buy order activity.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
